Assessing the viability of long-acting β₂-agonists in paediatric asthma patients: a pharmacokinetic/pharmacodynamic perspective

References

• Condemi JJ, Goldstein S, Kalberg C, et al. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Ann Allergy Asthma Immunol. 1999;82(4):383–389.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005;171(2):129–136.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. Revised 2015. [cited 2016 Mar 21]. Available from: http://www.ginasthma.org/
   Google Scholar
• National Asthma Education and Prevention Program. Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol. 2007;120(5 Suppl):S94–S138.
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Szefler S. Long-acting beta2 agonists and paediatric asthma. Lancet. 2006;367:286–288.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Han S, Shang J, et al. Effectiveness of drug treatment strategies to prevent asthma exacerbations and increase symptom-free days in asthmatic children: a network meta-analysis. J Asthma. 2015;52(8):846–857.
   PubMed Web of Science ®Google Scholar
• Lemanske RF Jr, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. 2010;362:975–985.
   PubMed Web of Science ®Google Scholar
• Ducharme FM, Ni Chroinin M, Greenstone I, et al. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev. 2010;(4):CD005533.
   PubMed Web of Science ®Google Scholar
• Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev. 2008;(3):CD006363.
   Google Scholar
• Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev. 2009;(2):CD006924.
   Google Scholar
• Rodrigo GJ, Moral VP, Marcos LG, et al. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review. Pulm Pharmacol Ther. 2009;22:9–19.
   PubMed Web of Science ®Google Scholar
• Kramer JM. Balancing the benefits and risks of inhaled long-acting beta-agonists--the influence of values. N Engl J Med. 2009;360:1592–1595.
   PubMed Web of Science ®Google Scholar
• Casares-Alonso I, Cano-Garcinuño A, Blanco-Quirós A, et al. Anti-asthmatic prescription variability in children according to age. Allergol Immunopathol (Madr). 2015;43(4):383–391.
   PubMed Web of Science ®Google Scholar
• Anderson WC 3rd, Szefler SJ. New and future strategies to improve asthma control in children. J Allergy Clin Immunol. 2015;136(4):848–859.
   PubMed Web of Science ®Google Scholar
• Ginsberg G, Hattis D, Sonawane B, et al. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci. 2002;66:185–200.
   PubMed Web of Science ®Google Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157–1167.
   PubMed Web of Science ®Google Scholar
• Batchelor HK, Marriott JF. Paediatric pharmacokinetics: key considerations. Br J Clin Pharmacol. 2015;79:395–404.
   PubMed Web of Science ®Google Scholar
• Mahmood I. Prediction of drug clearance in children: a review of different methodologies. Expert Opin Drug Metab Toxicol. 2015;11:573–587.
   PubMed Web of Science ®Google Scholar
• Skinner AV. Neonatal pharmacology. Anaesth Intensive Care Med. 2011;12:79–84.
   Google Scholar
• Murry DJ, Crom WR, Reddick WE, et al. Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos. 1995;23:1110–1116.
   PubMed Web of Science ®Google Scholar
• De Wildt SN, Kearns GL, Leeder JS, et al. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet. 1999;37:485–505.
   PubMed Web of Science ®Google Scholar
• Strolin Benedetti M, Whomsley R, Baltes EL. Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert Opin Drug Metab Toxicol. 2005;1:447–471.
   PubMed Web of Science ®Google Scholar
• Strolin Benedetti M, Baltes EL. Drug metabolism and disposition in children. Fundam Clin Pharmacol. 2003;17:281–299.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Testi R, Matera MG. Clinical pharmacokinetics of salmeterol. Clin Pharmacokinet. 2002;41(1):19–30.
   PubMed Web of Science ®Google Scholar
• Bartow RA, Brogden RN. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs. 1998;55:303–322.
   PubMed Web of Science ®Google Scholar
• Lecaillon JB, Kaiser G, Palmisano M, et al. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder Inhalation via aerolizerTM. Eur J Clin Pharmacol. 1999;55:131–138.
   PubMed Web of Science ®Google Scholar
• Taburet A-M, Schmit B. Pharmacokinetic optimisation of asthma treatment. Clin Pharmacokinet. 1994;26:396–418.
   PubMed Web of Science ®Google Scholar
• Morgan DJ. Clinical pharmacokinetics of beta-agonists. Clin Pharmacokinet. 1990;18:270–279.
   PubMed Web of Science ®Google Scholar
• Brogden RN, Faulds D. Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs. 1991;42:895–912.
   PubMed Web of Science ®Google Scholar
• Somers GI, Lindsay N, Lowdon BM, et al. A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007;35:1797–1805.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Page CP, et al. Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. Expert Opin Drug Metab Toxicol. 2014;10:129–137.
   PubMed Web of Science ®Google Scholar
• Harrell AW, Siederer SK, Bal J, et al. Metabolism and disposition of vilanterol, a long-acting β2-adrenoceptor agonist for inhalation use in humans. Drug Metab Dispos. 2013;41:89–100.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Olodaterol: a review of its use in chronic obstructive pulmonary disease. Drugs. 2015;75:665–673.
   PubMed Web of Science ®Google Scholar
• De Cock RFW, Piana C, Krekels EHJ, et al. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol. 2011;67(Suppl. S1):S5–S16.
   Google Scholar
• Sammons H. Ethical issues of clinical trials in children: a European perspective. Arch Dis Child. 2009;94:474–477.
   PubMed Web of Science ®Google Scholar
• Wildhaber JH, Devadason SG, Eber E, et al. Aerosol delivery to wheezy infants: a comparison between a nebulizer and two small volume spacers. Pediatr Pulmonol. 1997;23:212–216.
   PubMed Web of Science ®Google Scholar
• Devadason SG, Everard ML, MacErlan C, et al. Lung deposition from the Turbuhaler in children with cystic fibrosis. Eur Respir. 1997;10:2023–2028.
   PubMed Web of Science ®Google Scholar
• Chua HL, Collis GG, Newbury AM, et al. The influence of age on aerosol deposition in children with cystic fibrosis. Eur Respir J. 1994;7:2185–2191.
   PubMed Web of Science ®Google Scholar
• Mallol J, Rattray S, Walker G, et al. Aerosol deposition in infants with cystic fibrosis. Pediatr Pulmonol. 1996;21:276–281.
   PubMed Web of Science ®Google Scholar
• Rottier BL, Rubin BK. Asthma medication delivery: mists and myths. Paediatr Respir Rev. 2013;14:112–118.
   PubMed Web of Science ®Google Scholar
• Kuna P, Govoni M, Lucci G, et al. Pharmacokinetics and pharmacodynamics of an extrafine fixed pMDI combination of beclometasone dipropionate/formoterol fumarate in adolescent asthma. Br J Clin Pharmacol. 2015;80(3):569–580.
   PubMed Web of Science ®Google Scholar
• Berg E. In vitro properties of pressurized metered dose inhalers with and without spacer devices. J Aerosol Med. 1995;8 Suppl 3:S3–S10.
   Google Scholar
• Van Schayck CP, Donnell D. The efficacy and safety of QVAR (hydrofluoroalkane-beclomethasone diproprionate extrafine aerosol) in asthma (Part 2): clinical experience in children. Int J Clin Pract. 2004;58:786–794.
   PubMed Web of Science ®Google Scholar
• Agertoft L, Andersen A, Weibull E, et al. Systemic availability and pharmacokinetics of nebulised budesonide in preschool children. Arch Dis Child. 1999;80:241–247.
   PubMed Web of Science ®Google Scholar
• Chawes BL, Govoni M, Kreiner-Møller E, et al. Systemic exposure to inhaled beclometasone/formoterol DPI is age and body size dependent. Respir Med. 2014;108:1108–1116.
   PubMed Web of Science ®Google Scholar
• Oliver A, Van Buren S, Allen A, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of vilanterol, a novel inhaled long-acting β-agonist, in children aged 5-11 years with persistent asthma: A randomized trial. Clin Pharmacol Drug Dev. 2014;3:215–221.
   PubMed Web of Science ®Google Scholar
• Penna AC, Dawson KP, Manglick P, et al. Systemic absorption of salbutamol following nebulizer delivery in acute asthma. Acta Pediatr. 1993;82:963–966.
   PubMed Web of Science ®Google Scholar
• Bonnelykke K, Jespersen JJ, Bisgaard H. Age dependent systemic exposure to inhaled salbutamol. Br J Clin Pharmacol. 2007;64:241–244.
   PubMed Web of Science ®Google Scholar
• Govoni M, Piccinno A, Lucci G, et al. The systemic exposure to inhaled beclometasone/formoterol pMDI with valved holding chamber is independent of age and body size. Pulm Pharmacol Ther. 2015;30:102–109.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64:450–504.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Rogliani P, et al. β2-agonist therapy in lung disease. Am J Respir Crit Care Med. 2013;187:690–696.
   PubMed Web of Science ®Google Scholar
• Brink C, Duncan PG, Midzenski M, et al. Response and sensitivity of female guinea-pig respiratory tissues to agonists during ontogenesis. J Pharmacol Exp Ther. 1980;215:426–433.
   PubMed Web of Science ®Google Scholar
• Preuss JM, Rigby PJ, Goldie RG. The influence of animal age on beta-adrenoceptor density and function in tracheal airway smooth muscle. N Schmied Arch Pharmacol. 1999;360:171–178.
   Google Scholar
• Scarpace PJ, Abrass IB. Decreased beta-adrenergic agonist affinity and adenylate cyclase activity in senescent rat lung. J Gerontol. 1983;38:143–147.
   PubMedGoogle Scholar
• Vestal RE, A Jj W, Shand DG. Reduced beta adrenoceptor sensitivity in the elderly. Clin Pharmacol Ther. 1979;26:181–185.
   PubMed Web of Science ®Google Scholar
• Connolly MJ, Crowley JJ, Charan NB, et al. Impaired bronchodilator response to albuterol in healthy elderly men and women. Chest. 1995;108:401–406.
   PubMed Web of Science ®Google Scholar
• Ullah MI, Newman GB, Saunders KB. Influence of age on response to ipratropium and salbutamol in asthma. Thorax. 1981;36:523–529.
   PubMed Web of Science ®Google Scholar
• Bisgaard H. Effect of long-acting β2 agonists on exacerbation rates of asthma in children. Pediatr Pulmonol. 2003;36:391–398.
   PubMed Web of Science ®Google Scholar
• Tal A, Simon G, Vermeulen JH, et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol. 2002;34:342–350.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline Clinical Trial Register. SAM 40012 trial. [ cited 2016 Aug 15]. Available from: http://www.gsk-clinicalstudyregister.com
   Google Scholar
• Xia Y, Kelton CM, Xue L, et al. Safety of long-acting beta agonists and inhaled corticosteroids in children and adolescents with asthma. Ther Adv Drug Saf. 2013;4:254–263.
   PubMedGoogle Scholar
• Chauhan BF, Chartrand C, Ni Chroinin M, et al. Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev. 2015;11:CD007949.
   Google Scholar
• Kew KM, Beggs S, Ahmad S. Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids. Cochrane Database Syst Rev. 2015 May 21;(5):CD011316.
   Google Scholar
• Skoner DP. Pharmacokinetics, pharmacodynamics, and the delivery of pediatric bronchodilator therapy. J Allergy Clin Immunol. 2000;106(3 Suppl):S158–S164.
   PubMed Web of Science ®Google Scholar
• Pedersen S, Dubus JC, Crompton GK. The ADMIT series–issues in inhalation therapy. 5) Inhaler selection in children with asthma. Prim Care Respir J. 2010;19:209–216.
   PubMedGoogle Scholar
• Wildhaber J, Devadson SG, Hayden MJ, et al. Aerosol delivery to wheezy infants; a comparison between nebulizers and two small volume spacers. Pediatr Pulmonol. 1997;23:212–216.
   PubMed Web of Science ®Google Scholar
• Olsson B, Borgström L, Asking L, et al. Effect of inlet throat on the correlation between measured fine particles dose and lung deposition. In: Dalby R, Byron P, Farr S, editors. Respiratory drug delivery V. Buffalo Grove (IL): Interpharm Press; 1996. p. 273–281.
   Google Scholar
• Chawes BL, Govoni M, Piccinno A, et al. A clinical pharmacology study of fixed vs. free combination of inhaled beclometasone dipropionate and formoterol fumarate dry powder inhalers in asthmatic adolescents. Br J Clin Pharmacol. 2014;78:1169–1171.
   PubMed Web of Science ®Google Scholar
• Chou KJ, Cunningham SJ, Crain EF. Metered-dose inhalers with spacers vs nebulizers for pediatric asthma. Arch Pediatr Adolesc Med. 1995;149:201–205.
   PubMed Web of Science ®Google Scholar
• Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet. 2008;47:231–243.
   PubMed Web of Science ®Google Scholar
• Dunne J. The European regulation on medicines for paediatric use. Paediatr Respir Rev. 2007;8:177–183.
   PubMed Web of Science ®Google Scholar